Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $15.78
• Market Cap: $576.43M
• EPS: $-2.25
• 52-Week High: $16.33
• 52-Week Low: $3.35

Market Sentiment

Contineum Therapeutics, Inc. Class A Common Stock currently has a Bullish sentiment score of 0.16.

About Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company located in San Diego, California, focused on developing innovative oral small molecule therapies to address significant unmet medical needs in neuroscience, inflammation, and immunology. The company boasts a robust pipeline driven by advanced research capabilities and a commitment to scientific excellence, positioning itself to deliver effective treatments that enhance patient outcomes. With a strategic focus on addres...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Contineum Therapeutics, Inc. Class A Common Stock and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does CTNM pay dividends?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) does not currently pay a regular dividend.

What is CTNM's market cap?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a market capitalization of $576.43M with a current stock price of $15.78.